Navigation Links
New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
Date:11/1/2008

p>

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS. During treatment, patients' clinical status and hepatic function should be closely monitored, and PEGASYS treatment should be immediately discontinued if decompensation (Child-Pugh score greater than or equal to 6) is observed. Ischemic and hemorrhagic cerebrovascular events have been observed in patients treated with interferon alfa-based therapies, including PEGASYS. Events occurred in patients with few or no reported risk factors for stroke, including patients less than 45 years of age. Because these are spontaneous reports, estimates of frequency cannot be made and causal relationship between interferon alfa-based therapies and these events is difficult to establish.

The most common adverse events reported for PEGASYS and COPEGUS combination therapy observed in clinical trials were fatigue/asthenia (65 percent), headache (43 percent), pyrexia (41 percent), myalgia (40 percent), irritability/anxiety/nervousness (33 percent), insomnia (30 percent), alopecia (28 percent), neutropenia (27 percent), nausea/vomiting (25 percent), rigors (25 percent), anorexia (24 percent), injection site reaction (23 percent), arthralgia (22 percent), depression (20 percent), pruritus (19 percent) and dermatitis (16 percent).

Serious adverse events in hepatitis C trials included neuropsychiatric disorders (homicidal ideation, suicidal ideation, suicide attempt, suicide, psychotic disorder and hallucinations), serious and severe bacterial infections (sepsis), bone marrow toxicity (cytopenia and rarely, aplastic anemia), cardiovascular disorders (hypertension, supraventricular arrhythmias and myocardial infarction), hypersensitivity (including anaphylaxis), endocrine disorders (including thyroid disorders and diabetes mellitus), autoimmune disorders (including idiopathic thrombocytopenic purpura, thrombotic thromb
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New International Study Shows Women With Symptomatic Fibroids Delaying Treatment Despite Substantial Burden on Quality of Life
2. Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD
3. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
4. Grapes May Aid a Bunch of Heart Risk Factors, U-M Animal Study Finds
5. NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation
6. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
7. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
10. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
11. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  HyGreen, Inc., a leader in hand ... with RCA Medical, a subsidiary of Ascendis Health Limited, ... Each year, hundreds of millions of patients around ... organisms are transmitted from patient to patient via the ...
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... N.J. , Jan. 23, 2015  CytoSorbents Corporation ... commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce ... announced the receipt of $385,642, net of transaction ... of the Technology Business Tax Certificate Transfer Program ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3
... Tim Wentworth, group president for employer and key ... MHS ), is scheduled to present at the Lazard ... 17, 2010 in New York. (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO) ... The St. Regis Hotel is scheduled to begin at ...
... Despite national guidelines recommending that inhaled corticosteroid (ICS) ... with mild persistent asthma, a new study finds that ... drugs that combine an ICS and a long-acting beta ... noted based on pharmacy and medical claims. The analysis ...
Cached Medicine Technology:Medco to Present at the Lazard Capital Markets 7th Annual Healthcare Conference 2New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs 2New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs 3New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs 4
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort ... as the number one best large hotel for families in ... for their annual Travelers’ Choice Awards. , TripAdvisor represents ... is home to millions of unbiased and honest traveler reviews. ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in ... Player Health Alliance (PPHA). The PPHA's passion for others' ... including NFL greats, treated for obstructive sleep apnea (OSA) has ... the cause in the valley. The most recent plans for ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together by ... up to 30lbs in less than 12 weeks without traditional ... prompting an investigative review. , “Our Incredible Bulk review ... that allows the body to pack on a massive amount ...
(Date:1/22/2015)... 22, 2015 Blue Cross and Blue Shield ... exemplify what it means to “Live Fearless.” , ... to share their stories about how they or someone they ... others by living in the moment. By telling these types ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The federal court ... the U.S. District Court, Southern District of West Virginia has ... in that proceeding’s first bellwether trial. In an Order dated ... new trial after finding that C.R. Bard had not proven ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4
... Boys with asthma who are exposed to environmental tobacco ... other behavioral problems, according to researchers at Cincinnati Children,s ... ahead of print by the Journal of Developmental ... increase along with higher exposure levels, but they added ...
... Transgenomic,(OTC Bulletin Board: TBIO) today announced ... Texas through its technology transfer entity, the,Research ... exclusive license,to patents covering a method for ... the basis for the development of diagnostic ...
... - Over 11,000 people raced to wellness in Louisiana ... challenge event was the latest in a series of programs ... is part of a growing movement to help people live ... one of the country,s most obese states, Louisiana is continuing ...
... (Dec. 4, 2008) In a statewide survey of ... Research Institute at Harbor-UCLA Medical Center (LA BioMed) are ... according to the December issue of Los Angeles magazine. ... more than 30,000 medical professionals to compile the 2008 ...
... released the following statement in reaction to the latest Congressional ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070209/NYF043LOGO ) , ... that will only get worse if we allow America,s biggest ... these corporations go under -- taking with them the men ...
... division of Patient Safety Technologies, Inc. (OTC Bulletin Board:,PSTX), today ... become,one of its partners in helping to create a safer, ... at Leapfrog,s next two meetings in,December and February. , ... privileged to enter into an affiliation with,Leapfrog. We share a ...
Cached Medicine News:Health News:Study strengthens link between tobacco smoke and behavioral problems in boys with asthma 2Health News:Study strengthens link between tobacco smoke and behavioral problems in boys with asthma 3Health News:Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology 2Health News:Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology 3Health News:Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology 4Health News:Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology 5Health News:Transgenomic Obtains Exclusive License to Mitochondrial DNA Damage Detection Technology 6Health News:High Tech Wellness Inspires Louisiana 2Health News:LA BioMed researchers among Southern California Super Doctors 2Health News:AARP: Health Care and Pension Reform Critical to Economic Recovery 2Health News:AARP: Health Care and Pension Reform Critical to Economic Recovery 3Health News:SurgiCount Medical Joins The Leapfrog Group 2
... biocompatible, flexible, one-piece artificial cornea (keratoprosthesis) designed ... cornea., ,The World Health Organisation (WHO) reports ... million people worldwide, however only 100,000 people ... is due to a combination of inadequate ...
A comprehensive CPT surgical, radiological and anesthesia coding reference....
PDA-version of the leading portable drug reference....
PDA format of the well-known standard antimicrobial reference....
Medicine Products: